Venture Capital

Univ. Of Wash.-spinout Icosavax Raises $100M To Fund Vaccine Development Technology

by posted 5months ago 174 views
New funding: At a moment when vaccines are on everyone’s mind, a Seattle-based biotech company that has an unusual approach to vaccine production has raised $100 million in a Series B round. The startup creates computer-designed, virus-like particles that are used in vaccines to trigger immune responses. The new funding follows a $51 million round in October 2019. Icosavax has 17 employees. More on the vaccines: Icosavax is working on a COVID-19 vaccine, as well as vaccines to prevent less well known diseases: respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).